Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Home
Dasatinib is safe and active in pediatric CML (Gore et al., 2018)

Dasatinib is safe and active in pediatric CML (Gore et al., 2018)

Until recently, for pediatric patients with chronic myeloid leukemia (CML), imatinib was the only approved BCR-ABL1 targeted tyrosine kinase inhibitor (TKI). However, approximately 30% of patients discontinue imatinib as a result of resistance or intolerance.

The phase II international study in newly diagnosed (n=84) and in imatinib resistent or intolerant (n=29) CML patients presented here, showed that patients receiving dasatinib achieve rapid and deep responses, as summarized in the table below.

Cohort

3 months

6 months

12 months

24 months

Imatinib R/I cohort

55% MCyR

41% CCyR

66% CCyR

90% MCyR

76% CcyR

41% MMR

90% MCyR

83% CcyR

55% MMR

Newly diagnosed cohort

35% CCyR

64% CCyR

92% CcyR

52% MMR

94% CcyR

70% MMR

95% PFS

R/I=resistant/intolerant; McyR=major cytogenetic response; CcyR=complete cytogenetic response; MMR=major molecular response.

Read the full scientific article here: Gore L, Kearns PR, de Martino ML, Lee, De Souza CA, Bertrand Y, Hijiya N, Stork LC, Chung NG, Cardos RC, Saikia T, Fagioli F, Seo JJ, Landman-Parker J, Lancaster D, Place AE, Rabin KR, Sacchi M, Swanink R, Zwaan CM. J Clin Oncol;2018: May 1;36(13):1330-1338. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial. - PubMed - NCBI